not sure about the “isn’t enough to make money” point…. Doesn’t CarT treatment costs run into hundreds of k - which suggests a few hundred patients receiving this treatment if available would be an extremely healthy level of (yearly) returns - loads of assumptions naturally, but I certainly don’t think they’re pursuing a commercial white elephant re GBM?
CHM Price at posting:
3.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)